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ABSTRACT
Epithelial ovarian carcinoma accounts for 90% of all ovarian cancer and is the 
most deadly gynecologic malignancy. Recent studies have suggested that fallopian 
tube fimbriae can be the origin of cells for high-grade serous subtype of epithelial 
ovarian carcinoma (HGSOC). A mouse HGSOC model with conditional Dicer-Pten 
double knockout (Dicer-Pten DKO) developed primary tumors, intriguingly, from 
the fallopian tube stroma. We examined the growth and epithelial phenotypes of 
the Dicer-Pten DKO mouse tumor cells contributable by each gene knockout. Unlike 
human ovarian epithelial cancer cells that expressed full-length E-cadherin, the 
Dicer-Pten DKO stromal tumor cells expressed cleaved E-cadherin fragments and 
metalloproteinase 2, a mixture of epithelial and mesenchymal markers. Although the 
Dicer-Pten DKO tumor cells lost the expression of mature microRNAs as expected, they 
showed high levels of tRNA fragment expression and enhanced AKT activation due 
to the loss of PTEN function. Introduction of a Dicer1-expressing construct into the 
DKO mouse tumor cells significantly reduced DNA synthesis and the cell growth rate, 
with concurrent diminished adhesion and ZO1 epithelial staining. Hence, it is likely 
that the loss of Dicer promoted mesenchymal-epithelial transition in fallopian tube 
stromal cells, and in conjunction with Pten loss, further promoted cell proliferation 
and epithelial-like tumorigenesis.
INTRODUCTION
Epithelial ovarian cancer is the deadliest of all 
gynecologic malignancies and is the fifth leading cause of 
cancer death in females in the United States [1]. Because 
the lack of a highly specific early detection marker and 
frequent relapses, the majority of ovarian cancer patients 
are usually diagnosed at an advanced stage and have a 
5-year survival rate of about 30% [1]. High-grade serous 
ovarian carcinoma (HGSOC) is the most common and 
aggressive type of ovarian neoplasm with epithelial cells 
resembling those of fallopian tube, comprising about 50% 
of primary epithelial ovarian tumors [2]. Historically, 
ovarian surface epithelial (OSE) cells on the ovarian 
surface epithelium and the associated cortical inclusion 
cysts have been suggested as the cells of origin for ovarian 
cancer [3, 4]. Recent studies, however, have suggested that 
epithelial cells in the distal fallopian tube can be the cells 
of origin for the development of HGSOC. Serous tubal 
intraepithelial carcinomas (STIC) with both p53 mutations 
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and expression of γ-H2AX, evidence of DNA damage 
that is frequently observed in HGSOC, are proposed as a 
potential precursor for HGSOC. [5–8].
Several mouse models with genomic manipulations 
in specific organ sites have been established for ovarian 
tumors originating from ovarian surface epithelia [9–
12] and fallopian tube [13], respectively. Mechanistic 
studies of these mouse models may provide insights 
into the mechanisms by which native human ovarian 
cancer develops and is regulated. One recent mouse 
model employed anti-Muüllerian hormone receptor type 
2-directed Cre (Amhr2-Cre) to specifically knockout both 
Dicer and Pten genes in the mouse female reproductive 
tract [14]. The Dicer-Pten DKO (Dicerflox/flox Ptenflox/
flox Amhr2cre/+) mice developed early serous carcinomas 
in the fallopian tube, which mimicked the morphology 
and clinical manifestation in human HGSOC. However, 
intriguingly, the primary epithelial tumors were found 
to arise from cells of a mesenchymal lineage in the 
stroma of the fallopian tube [14]. The contribution 
of Pten dysregulation in ovarian cancer has been well 
researched in human ovarian cancer and mouse models 
[9, 10, 15–17], and the tumors arose from epithelial 
cells in the mouse models. But for Dicer1, germline 
mutations have been found in familial pleuropulmonary 
blastoma, a rare pediatric lung cancer [18], embryonal 
rhabdomyosarcomas [19], and familial multinodular 
goiter [20]. Interestingly, somatic Dicer1 hotspot 
missense mutations with defective Dicer1 function 
in 5p miRNA production were commonly found in 
nonepithelial ovarian tumors, in particular in 60% of 
Sertoli-Leydig cell tumors, and rarely in epithelial 
ovarian and endometrial carcinomas [21, 22]. Given 
the predominance of Dicer1 mutations in nonepithelial 
ovarian tumors, the appearance of epithelial HGSOC 
tumors arising from the fallopian tube stroma in the 
Dicer-Pten DKO mouse model might be likely due to 
the loss of Dicer1 function.
Molecular characterization of ovarian tumors 
and cancer cell lines has shown that they are more 
epithelial-like than normal ovarian surface epithelia and 
the derived cell lines [3, 4, 23, 24], which possess both 
mesenchymal and epithelial characteristics for post-
ovulatory wound healing and tissue homeostasis [3, 25]. 
The expression of adherens junction protein E-cadherin 
was elevated in ovarian tumors [26] and ectopic 
expression of E-cadherin in OSE caused mesenchymal-
epithelial transition and the resulting cells formed 
tumors in immunodeficient mice [27, 28]. Our previous 
sequential in vitro three-dimensional culture models 
have also shown that E-cadherin function is important 
for ovarian inclusion cyst formation and ovarian tumor 
invasion [29]. In this study, we examined the epithelial 
phenotypes of the Dicer-Pten DKO mouse tumor cells 
and contribution of each knockout genes in tumor 
phenotypes.
RESULTS
Epithelial phenotypes of the Dicer-Pten DKO 
mouse tumors and cancer cell lines
We first investigated the epithelial phenotypes 
of the Dicer-Pten DKO mouse tumors by performing 
immunohistochemistry for the expression of epithelial 
and mesenchymal markers (Figure 1A). Both the 
primary and metastatic tumors stained positive for PAX8, 
a marker for embryonic Müllerian ducts, human fallopian 
tubes, and serous subtype of ovarian carcinomas [30]. 
The tumors also had high expression of cytokeratins. 
However, the tumors showed modest positive staining 
of adherens junction protein, E-cadherin, and matrix 
metalloproteinase-2 (MMP2) that are associated with 
epithelial-mesenchymal-transition (EMT). We also 
examined the epithelial phenotypes of the Dicer-Pten 
DKO fallopian tube tumor-derived cancer cell lines 
(FTdT172 and FTdT967) together with two mouse cancer 
cell lines originated from the ovarian surface epithelium, 
OVdT4306 and OVdT4088, which were derived from 
K-rasG12D/+Pten-/- and K-rasG12D/+ TP53-/- mice, respectively, 
[9]. We also employed two human ovarian cancer cell 
lines, OVCA432 and MCAS, in the comparison. Western 
blot analysis of the cell lysates (Figure 1B) showed that 
all cancer cell lines except OVCA432 expressed epithelial 
cytokeratins. The human ovarian cancer cell lines 
expressed high levels of full-length E-cadherin proteins, 
whereas the mouse ovarian tumor- and fallopian tube 
tumor-derived cancer cell lines expressed only E-cadherin 
protein fragments with smaller molecular weights. 
Furthermore, as reported before [29], the human ovarian 
cancer cells did not express MMP2, which was expressed 
in the mouse tumor cell lines. Within the mouse tumor 
cell lines, the ovarian tumor-derived OVdT4088 and 
OVdT4306 cancer cells expressed the TGFβ downstream 
target phosphorylated Smad2, while the Dicer-Pten DKO 
cancer cell lines showed very little expression. Instead, the 
Dicer-Pten DKO cancer cell lines had higher expression 
of TGFβ downstream transcription factors Slug and 
Snail. Hence, the expression analysis showed that the 
Dicer-Pten DKO mouse fallopian tube tumors and cancer 
cells expressed a mixture of epithelial and mesenchymal 
markers, that were very distinct from human epithelial 
ovarian cancer cells.
Investigation of cell growth and small RNA 
expression phenotypes of the Dicer-Pten DKO 
mouse tumors and cancer cell lines
As HGSOC is a highly aggressive tumor, we 
compared the growth rate among the mouse tumor cell lines 
(Figure 2A). Both Dicer-Pten DKO cancer cell lines and 
the OVdT4306 cancer line showed enhanced growth rate 
compared with the K-rasG12D/+ TP53-/- OVdT4088 mouse 
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Figure 1: The Dicer-Pten DKO mouse tumor cells express a mixture of epithelial and mesenchymal markers. 
A. Immunohistochemistry of the Dicer-Pten DKO mouse tumor tissues for different markers. Scale bars represent 50μm. B. Western blot 
analysis of marker expression in different cell lysates. The position of the full-length E-cadherin is marked by an arrowhead. β–actin was 
used as loading control.
Figure 2: The Pten disruption contributed to the rapid proliferation of the Dicer-Pten DKO mouse cancer cells. A. Cell 
growth assay to compare the growth rates of different mouse cancer cell lines. B. Confocal microscopic images of three-dimensional in vitro 
spheres formed by the Dicer-Pten DKO mouse cancer cell lines in Collagen I matrix and stained for β–catenin (red), F-actin (green) and 
nucleus (blue). C. Western blot analysis for the expression for growth and metabolic markers. β–actin was used as loading control.
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cancer cell line. We also tested the two Dicer-Pten DKO 
cancer cell lines in a sequential three-dimensional culture 
system which we have previously developed [29]. The 
FTdT967 line showed more aggressive growth and invaded 
into the collagen I extracellular matrix after 3 days of 
growth (Figure 2B), suggesting that this line is derived from 
a tumor that may have a more aggressive phenotype. Both 
Dicer-Pten DKO tumor lines and the OVdT4306 cancer 
cell line shared genomic Pten deletion, which affected the 
PI3K/AKT key metabolic and cell growth pathway. We 
investigated the status of AKT pathway in different cancer 
cell lines by Western blot analysis (Figure 2C). These three 
mouse cancer cell lines showed increased phospho-AKT 
expression when compared with the OVdT4088 line, and 
expectedly, showed stronger expression of the downstream 
phospho-mTOR target. However, within these four mouse 
cell lines, there was no change in phospho-AMPK, another 
master regulator of cell growth and metabolism that can 
affect mTOR activity [31].
As our preliminary qRT-PCR test showed some 
minor differences in the miRNA expression in the Dicer-
Pten DKO cancer cells (data not shown), we carried out 
a miRNA transcriptomic profiling of the Dicer-Pten DKO 
tumor lines 172, 177, and 967. For comparison, we also 
determined the miRNA profiles from RNA isolated from 
normal mouse fallopian tubes, and the two ovary-derived 
lines. The results of the profiling (Figure 3A and Figure 
3B) showed that while most of all the miRNA species 
examined showed downregulation in the Dicer-Pten 
DKO tumor lines, there were significantly elevated levels 
of miR-720 and miR-1937a, b, and c in the DKO tumor 
lines, which according to miRBase database (http://www.
mirbase.org/index.shtml), belonged to tRNA fragments. 
qRT-PCR performed on the RNA preparations validated 
the elevated expression of miR-720 tRNA fragments in 
the three Dicer-Pten DKO tumor lines relative to normal 
fallopian tube and the other cancer cell lines (Figure 3C, 
P < 0.05). Hence, excessive tRNAs were expressed in 
Figure 3: The Dicer-Pten DKO mouse cancer cells expressed elevated levels of tRNA fragments. A. The result of the 
Nanostring® nCounter miRNA expression assay. The relative expression of mmu-miR-720, mmu-miR-1937a, 1937b, and 
1937c in different cell lines is shown in the inset. B. Normalized counts of the miRNAs representing tRNA fragments that 
are elevated (red), as well as some other miRNAs that are significantly down-regulated (dark) in the Dicer-Pten DKO mouse 
cancer cells relative to normal fallopian tube (FT) and ovary-derived tumor cell lines. C. qRT-PCR of mmu-miR-720 in 
different RNA preparations.
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these DKO lines despite the downregulation of miRNA 
expression.
Introduction of a Dicer1-expression construct 
into the Dicer-Pten DKO mouse cancer cells 
reversed the growth and epithelial phenotypes
To investigate whether Dicer1 knockout caused the 
epithelialization of the mouse fallopian tube stromal cells 
and affected the growth of the Dicer-Pten DKO cancer 
cells, a FLAG-tagged Dicer1-expression construct was 
introduced into both FTdT172 and FTdT967 cells by 
lentiviral infection and the resulting cells were tested for 
FLAG-Dicer1 expression (Figure 4A) and cell growth and 
epithelial phenotypes. Compared to control cells, Dicer1-
lentivirus infected cells showed significant reduction in 
growth rate (Figure 4B). Cell cycle analysis of BrdU- 
and propidium iodide-labeled cells by flow cytometry 
also showed that the Dicer1-lentivirus infected cells had 
significant reduction in S and G2M phases in the cell 
cycle (Figure 4C). Intriguingly, Dicer1-lentivirus infected 
FTdT967 cells showed an additional subpopulation of 
cells between G1 and G2/M. An adhesion assay showed 
that the Dicer1-lentivirus infected FTdT172 cells showed 
significant reduced adherence to collagen I extracellular 
matrix than the control cells (Figure 4D, P = 0.007). The 
Dicer1-lentivirus infected FTdT967 cells also showed 
reduced, albeit not significant, cell adherence when 
compared with the control cells. Nevertheless, they 
demonstrated loss of membrane-bound expression of the 
tight junction-associated signaling protein ZO-1 when 
compared with control cells (Figure 4E).
DISCUSSION
Recent studies have suggested that the epithelial 
cells in distal fallopian tube can be the cells of origin 
for the development of HGSOC [5–8]. A genetically 
engineered mouse model that disrupted Brca1/Brca2, 
Tp53, and Pten genes specifically in fallopian tube 
epithelial cells developed carcinoma that resembled 
HGSOC [13]. The fact that the tumor development was 
preventable with the removal of fallopian tube, but not 
with the removal of the ovaries supported the notion 
of fallopian tube origin of HGSOC. It is interesting to 
note that the Dicer-Pten DKO mouse model developed 
HGSOC-like tumors originating from the stroma of 
fallopian tube[14], as human HGSOC tumor cells are 
believed to be derived from epithelial cells that express 
many epithelial markers [23, 24]. We examined the 
tumor tissues and derived cancer cell lines and showed 
that the tumor cells expressed a mixture of epithelial and 
mesenchymal markers (Figure 1). Actually, the marker 
expression pattern of the Dicer-Pten DKO tumor cells was 
similar to that represented by the mouse model established 
from the mesothelial-like ovarian surface epithelial cells 
[9]. While both fallopian tube tumor- and ovarian tumor-
derived mouse model cell lines expressed epithelial 
cytokeratins, they expressed only E-cadherin cleaved 
fragments and the EMT marker MMP2. The mouse 
cancer cell lines also expressed higher levels of TGFβ 
pathway downstream effector phosphorylated Smad2 
or transcription factors Slug and Snail. Therefore, while 
these tumors established epithelial-like properties, they 
maintained certain mesenchymal characteristics that were 
distinct from human HGSOC cells. It is also true that the 
fast growing mouse tumor cells would detach as skin when 
confluent (data not shown), suggesting some mesenchymal 
nature of these mouse cancer cells was preserved.
Given the predominance of Dicer1 mutations in 
nonepithelial ovarian tumors [21], it was expected that 
the knockout of the Dicer1 gene was responsible for the 
epithelialization of the mouse mesenchymal cells to form 
epithelial tumors in the Dicer-Pten DKO mouse model. 
Indeed, introduction of a Dicer1-expressing construct to 
the Dicer-Pten DKO mouse cancer cells reversed some 
epithelial phenotypes such as cell adhesion (Figure 4D). 
Even though the more aggressive growing FTdT967 
cells did not show significant reduction in cell adhesion 
after the reintroduction of Dicer1, the resulting cells 
nevertheless showed loss of ZO-1 membrane localization 
of the control cells (Figure 4E). ZO-1 is a tight junction-
associated signaling protein that is important for epithelial 
cell differentiation [32], the cytoplasmic distribution of 
ZO-1 in the Dicer1-reintroduced FTdT967 cells suggested 
that these cells lost the epithelial phenotype as did the 
Dicer1-reintroduced FTdT172 cells. Hence, loss of Dicer1 
in the Dicer-Pten DKO mouse model likely contributed 
to the epithelialization of stromal cells. Specific 
knockouts of Dicer1 in other mouse cell types have been 
reported to affect various cell differentiation and organ 
development. Disrupting Dicer1 function specifically in 
thyrocytes has shown downregulation of thyrocyte cell 
adhesion proteins and cell differentiation, which led to 
severe hypothyroidism and shortened life span [33]. It is 
also of interest to note that loss of Dicer in epicardium-
derived progenitor cells impaired EMT of the progenitor 
cells and a reduction in epicardial cell proliferation and 
differentiation into different cell lineages [34]. Hence, 
it is important to delineate the consequences of Dicer1 
dysregulations in a cell context-dependent manner.
We next investigated the contribution of Dicer 
and Pten gene knockouts on cell growth. Since Pten 
is known for suppressing PI3K/AKT pathway for 
cell growth and cell metabolism, the effects of Pten 
knockout on the activation of AKT and fast cell growth 
are evident in our assays (Figure 2). Furthermore, our 
miRNA profiling experiment resulted in the identification 
of tRNA overexpression in the Dicer-Pten DKO mouse 
tumors relative to normal fallopian tube cells (Figure 
3). PTEN has been reported to act through PI3K/
AKT/mTOR pathway to suppress RNA polymerase 
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III-mediated tRNA transcription [35, 36] and enhanced 
RNA polymerase III activity has been shown to promote 
oncogenic transformation [37, 38]. Individual tRNA 
fragments such as miR-720 have also been reported to 
promote cell migration [39] and represent a signature of 
breast cancer-derived extracellular vesicles [40]. Hence, 
it is likely that the loss of Pten in the Dicer-Pten DKO 
mouse model resulted in upregulation of RNA polymerase 
Figure 4: Introduction of a Dicer1-expression construct reversed the epithelial and growth phenotypes of the Dicer-
Pten DKO mouse cancer cells. A. Western blot to confirm the expression of FLAG-tagged Dicer1 in the lentivirus-infected cancer 
cells. β–actin was used as loading control. B. Cell growth assay to compare the growth rates of control and lentivirus-infected cancer 
cell lines. *, P < 0.005; #, P < 0.02. C. Flow cytometric density graphs to show the BrdU incorporation and cell cycles of the mouse 
cancer cell lines. The Y-axis represents the FITC fluorescence of BrdU labeled cells, whereas the X-axis represents the propidium iodide 
(PI) fluorescence. The boxed areas show the percentages of cell populations in G0/G1 phase (R4), G2/M phase (R5), and S phase (R6), 
respectively. D. Relative adhesion of different cell lines to collagen I extracellular matrix. The reading of FTdT172 cells was defined as 1. 
E. Fluorescence micrographs of ZO-1 staining (green) in both FTdT967 cells (top) and FTdT967 cells infected with Dicer1-expressing 
lentivirus (bottom). The DAPI-stained nuclei were shown in blue.
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III transcription and the tRNA overexpression contributed 
to oncogenic transformation of the fallopian tube stromal 
cells.
Besides the contribution by Pten disruption, our 
studies showed that Dicer1 disruption also contributed 
to the rapid cell proliferation of the DKO mouse cancer 
cells (Figure 4B and 4C). Our finding is consistent 
with the report by Chen et al. [22] that cancer cells 
harboring Dicer1 hotspot mutants that had lost 5p 
miRNA biogenesis, showed increased proliferation 
rate and upregulated expression of cell cycle promoting 
genes compared to cancer cells with wild-type Dicer1, 
suggesting the tumor-suppressing effect of Dicer1 in wild-
type cells. Similar to the Dicer1 hotspot mutant cells, the 
Dicer-Pten DKO mouse tumor cells showed significant 
reduced expression of miRNAs such as let-7 and miR-
125 (Figure 3B), which have been shown to harbor tumor 
suppressor functions [22, 41].
In conclusion, our studies have delineated the 
contribution of the Dicer and Pten disruptions to the DKO 
tumor cells originated in fallopian tube stroma. The 
loss of Pten contributed to the activated AKT pathway 
and increased RNA polymerase III transcription, 
which led to rapid proliferation of the cancer cells. 
However, disruption of Dicer1 played a dominant role 
in epithelialization of fallopian tube stromal cells, and 
in conjunction with Pten loss, drove these mesenchymal 
cells to rapid growth and epithelial-like tumorigenesis. 
Dicer1 dysregulations in epithelial cancers like ovarian 
and endometrial carcinomas are not as common as in 
nonepithelial cancers. The results of Cancer Genome 
Atlas (TCGA) genomic analyses of HGSOC revealed 
that 2.5% of HGSOC had alterations of Dicer1 gene 
[42]. Similar to the study of Dicer1 hotspot mutations in 
endometrial cancer [43], further studies of the potential 
role of Dicer1 dysregulations in affecting stromal cells 
in fallopian tube will provide insights into this potential 
route of ovarian cancer development.
MATERIALS AND METHODS
Cell lines and mouse tumor tissues
The Dicer-Pten DKO (Dicerflox/flox Ptenflox/floxAmhr2cre/+) 
mouse tumors and cancer cell lines have been previously 
described [14]. As a reference, the two mouse ovarian cancer 
cell lines derived from K-rasG12D/+Pten-/- and K-rasG12D/+ 
TP53-/- mice, respectively, [9] were used. Ovarian cancer 
cell lines OVCA432 and MCAS have been described before 
[44]. The human ovarian cancer cell lines were grown in 
medium 199 (Sigma-Aldrich, St. Louis, MO) and MCDB 
105 (Sigma-Aldrich, St. Louis, MO) (1:1) supplemented 
with 10% fetal calf serum (FCS). The mouse tumor cell 
lines were cultured with DMEM-F12 HAM medium (Life 
Technologies, Grand Island, NY) plus 10% FCS.
Immunohistochemistry
Immunohistochemistry (IHC) was performed 
on archived formalin-fixed, paraffin-embedded Dicer-
Pten DKO mouse tumors tissues. Standard xylene 
deparaffinization, rehydration with a descending series of 
ethanol solutions, antigen retrieval (Vector Laboratories, 
Burlingame, CA), and blocking of endogenous 
peroxidases in 0.3% H
2
O
2
 were performed as described 
before [44]. 3, 3 –diaminobenzidine (DAB) horseradish 
peroxidase substrate kit was used for color development 
(Vector Laboratories, Burlingame, CA).
Cell growth assay, three-dimensional cultures, 
and Western blot analysis
Cell growth study was performed by seeding 5x103 
cells per well in 96-well microtiter plates and the growth 
was determined by measuring methylthiazol tetrazolium 
(MTT) (5 mg/mL in PBS, Sigma-Aldrich, Natick, MA) 
incorporation on different days. Absorbance at 562 nm 
was determined on an ELx800 absorbance microplate 
reader (Bio-Tek, Winooski, VT). All the growth assays 
were performed in triplicates and repeated twice.
For three-dimensional cultures, single mouse cancer 
cells were allowed to form spheroids in 2% Matrigel 
(BD Biosciences, San Jose, CA), and the spheroids were 
transferred to Collagen I extracellular matrix (Sigma-
Aldrich, St. Louis, MO) for 3 days, fixed and stained 
with antibody for β-catenin (BD Biosciences, San Jose, 
CA) and phalloidin (Invitrogen, Carlsbad, CA) for 
F-actin, countered stained with Sytox Green (Invitrogen, 
Carlsbad, CA) as described before [29]. Confocal images 
were captured using a Leica SP5 confocal microscope 
(Leica Microsystems, Bannockburn, IL) and analyzed 
by the Leica LAS AF software (Leica Microsystems, 
Bannockburn, IL).
Total cell lysates were prepared using RIPA lysis 
buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% 
Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate, 
supplemented with protease and phosphatase inhibitor 
cocktail tablets (Roche Diagnostics Corporation, 
Indianapolis, IN)). Proteins were resolved using 
standard SDS-PAGE, transferred to PVDF membrane 
(ThermoFisher Scientific, Waltham, MA) and probed 
with different antibodies. Pierce ECL Western Blotting 
substrate (ThermoFisher Scientific, Waltham, MA) was 
used for signal detection.
RNA extraction, NanoString profiling, and 
quantitative real-time reverse-transcription PCR 
(qRT-PCR)
TRIzol reagent (Life Technologies, Grand Island, 
NY) was used to extract RNA from cell cultures and 
tumor tissues. miRNA Expression profiling was performed 
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using nCounter miRNA expression assay (Nanostring® 
Technologies, Seattle, WA). TaqMan MicroRNA Reverse 
Transcription Kit and TaqMan MicroRNA assay kits 
(Applied Biosystems, Foster City, CA) were used for 
qRT-PCR determination of miRNA levels, performed on a 
7300 Real-Time PCR System (Applied Biosystems, Foster 
City, CA). RNU6B RNA was used as the internal control 
to normalize sample input. Gene expression levels were 
determined using 2 -ΔΔCT method [45].
Introduction of a Dicer1-expression construct 
into the Dicer-Pten DKO cancer cells and cell 
growth and adhesion analyses
A lentiviral FLAG-tagged Dicer1-expression 
construct EX-H0470-Lv101 was purchased from 
GeneCopoeia, Inc. (Rockville, MD). Lentiviral 
transduction particles were prepared by transfecting the 
lentiviral construct together with ViraPower™ Lentiviral 
Packaging Mix (ThermoFisher Scientific, Waltham, 
MA) into 293FT cells according to the manufacturer’s 
recommendation. The expression of Dicer1 in transduced 
FTdT172 and FTdT967 tumor cells was confirmed 
by Western blot analysis using both a FLAG antibody 
(Cell Signaling Technology, Danvers, MA) and a Dicer1 
antibody (Bethyl Laboratories, Montgomery, TX).
For BrdU incorporation and cell cycle analysis, cells 
were incubated with 10 μM of BrdU (Sigma-Aldrich, St. 
Louis, MO) for 1 h. After trypsinization, cells were fixed 
with 70% ethanol and chromosomal DNA was denatured 
using 2N HCl/0.5% Trion X-100 and neutralized using 
0.1M Na
2
B
4
O
7
 (Sigma-Aldrich, St. Louis, MO). After 
resuspension, cells were labeled with FITC-conjugated 
anti-BrdU antibody (BD Biosciences, San Jose, CA) and 
5 μg/mL of propidium iodide (Sigma-Aldrich, St. Louis, 
MO), and analyzed using a BD Accuri™ C6 cytometer 
(BD Biosciences, San Jose, CA).
Cell adhesion assay was performed using the 
Collagen I cell adhesion strips from Millicoat™ Screen 
kit ECM205 (EMD Millipore, Billerica, MA). 1x104 cells 
were seeded to the strip wells and allowed to incubate for 
1 hour. Nonadherent cells were washed away by phosphate 
buffered saline and the attached cells were stained using 
0.2% crystal violet. The stain was solubilized in a 50:50 
mixture of 0.1M sodium phosphate, pH 4.5 and 50% 
ethanol and read at 562 nm. For immunofluorescence, 
the mouse cells growing in an 8-well chamberslide 
(BD Biosciences, San Jose, CA) were fixed in 4% 
paraformaldehyde (Sigma-Aldrich, St. Louis, MO) and 
permeabilized with PBS containing 0.5% Triton X-100 
(Sigma-Aldrich, St. Louis, MO). After blocking with 
10% FBS, anti-ZO1 primary antibody (EMD Millipore, 
Billerica, MA) and Alexa Fluor 647-conjugated anti-
mouse secondary antibody (Invitrogen, Carlsbad, CA) 
were added sequentially between washes. A mounting 
medium with DAPI (Vector Laboratories, Burlingame, 
CA) was used for counterstaining. Microscopic images 
were captured by a Leica DM IRE2 fluorescence 
microscope (Leica Microsystems, Bannockburn, IL) and 
analyzed by the OpenLab Cell Imaging System software 
(Leica Microsystems, Bannockburn, IL).
Statistical analysis
All calculations were performed with MINITAB 
statistical software (Minitab, State College, PA). 
Significance of differences was determined using 2-tailed 
T-Test. A P-value of less than 0.05 was considered 
statistically significant for all tests.
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